Download Full Text (415 KB)


  • Innovative Trial Investigates Molecular Drivers of Triple-Negative Breast Cancer: A new clinical trial focusing on molecular biomarkers of triple-negative breast cancer (TNBC) is attempting to advance targeted therapy against the deadly disease.
  • Smac Mimetics Show Activity against Myelofibrosis: Not all cases of myelofibrosis respond well to ruxolitinib, the only drug approved for this disease. However, early studies indicate that a new class of drugs, Smac mimetics, can achieve a response in some patients with myelofibrosis.
  • Urothelial Cancer Subtypes Predict Treatment Response: Subtypes of urothelial cancer identified through gene expression profiling predict which patients are most likely to respond to neoadjuvant cisplatin-based chemotherapy, according to research from The University of Texas MD Anderson Cancer Center. These findings will pave the way for a more personalized approach to treatment for urothelial cancers, including difficult-to-treat muscle-invasive bladder cancer.
  • HOUSE CALL: How Smoking Affects Appearance-Tobacco smoke causes premature aging, other cosmetic problems

Publication Date



The University of Texas MD Anderson Cancer Center


Houston, Texas


Moulder, Stacy; Symmans, W. Fraser; Pemmaraju, Naveen; Carter, Bing; Verstovsek, Srdan; Siefker-Radtke, Arlene; Choi, Woonyoung; McConkey, David; Borthakur, Gautam; Triple Negative Breast Neoplasms; Precision Medicine; Molecular Targeted Therapy; Clinical Trials as Topic; Myeloproliferative Disorders; Urinary Bladder Neoplasms; Lung Neoplasms; Tobacco Smoking; Aging, Premature; Gene Expression Profiling.


History of Science, Technology, and Medicine | Oncology

Conditions Governing Access


OncoLog, Volume 61, Number 11-12, November - December 2016